RxDoctor Payments Data

Funchi Tu, MD

Internal Medicine · Las Vegas, NVNPI 1497927610

Payments from drug & device makers

$2,048in general payments, 2019–2025

Across 120 payments — averaging $17.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$1K
  • Amarin Pharma, Inc.$348
  • AstraZeneca$346
  • Amgen$102
  • Redhill Biopharma Inc.$56
  • Chiesi USA, Inc.$23
  • plus $97 from 6 others

What the payments were for

  • Food & beverage$2,03799%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,048 in reported general payments places this provider in the 80th percentile of 1,071 internal medicine providers in Nevada.

See all internal medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$24,627
Medicare patients
44
Services billed
216

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide20$43,345
VascepaIcosapent Ethyl45$39,298
FarxigaDapagliflozin Propanediol23$31,003
JardianceEmpagliflozin18$28,506
JanuviaSitagliptin Phosphate12$20,461
VemlidyTenofovir Alafenamide11$15,601
SymbicortBudesonide/Formoterol Fumarate14$3,080
Omega-3 Acid Ethyl Esters16$2,824
Glipizide12$1,062
Atorvastatin Calcium177$1,006
Amlodipine Besylate126$713
Rosuvastatin Calcium87$614
Losartan Potassium80$535
Albuterol Sulfate HfaAlbuterol Sulfate20$530
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav59$455

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$16$43,34520 claims
AstraZenecaFarxiga, Symbicort$346$34,08437 claims
Boehringer IngelheimJardiance$18$28,50618 claims
GileadVemlidy$1,076$15,60111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,071 internal medicine providers in Nevada.

Other internal medicine in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →